BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23313194)

  • 1. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
    Lee S; Yoon CY; Byun SS; Lee E; Lee SE
    J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
    Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
    Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of c-FLIP(L) enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells.
    Chen F; Guo J; Zhang Y; Zhao Y; Zhou N; Liu S; Liu Y; Zheng D
    Cancer Sci; 2009 May; 100(5):940-7. PubMed ID: 19243385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
    Yang BF; Xiao C; Li H; Yang SJ
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
    Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
    Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.
    Abedini MR; Qiu Q; Yan X; Tsang BK
    Oncogene; 2004 Sep; 23(42):6997-7004. PubMed ID: 15258564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells.
    Yoon SJ; Park I; Kwak C; Lee E
    Oncol Rep; 2003; 10(5):1363-7. PubMed ID: 12883708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
    Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effects of kazinol A derived from Broussonetia papyrifera on human bladder cancer cells, T24 and T24R2.
    Park S; Fudhaili A; Oh SS; Lee KW; Madhi H; Kim DH; Yoo J; Ryu HW; Park KH; Kim KD
    Phytomedicine; 2016 Nov; 23(12):1462-1468. PubMed ID: 27765366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
    Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
    Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling.
    Kamarajan P; Sun NK; Chao CC
    Biochem J; 2003 Nov; 376(Pt 1):253-60. PubMed ID: 12911332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
    Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
    Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
    Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
    Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S; Ng CP; Bonavida B
    Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation.
    Mawji IA; Simpson CD; Hurren R; Gronda M; Williams MA; Filmus J; Jonkman J; Da Costa RS; Wilson BC; Thomas MP; Reed JC; Glinsky GV; Schimmer AD
    J Natl Cancer Inst; 2007 May; 99(10):811-22. PubMed ID: 17505076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.